In particular, the Aggrastat-to-Zocor (A to Z) trial demonstrated that the clinical outcome of patients with acute coronary syndromes significantly improves when the hs-CRP levels are lowered below 2 mg/L [16]. This evidence concerns the gene CRP and acute coronary syndrome.